True - it doesn't look like IDRA will have any major catalysts NR - filings of multiple IND's, announcements of more early stage research on their other platforms. Initiation of Waldenström’s lymphoma 1/2 trial first half 14 and diffuse large B-cell lymphoma ph1/2 second half. We'll see maturation of preclinical evidence for gene silencing tech this year when the company selects specific disease targets from preclinical data. IMO-8400 - have added high dose cohort results coming 2nd half and the 2 orphan disease indication apps will be submitted to FDA. Maybe they'll reach target of starting IMO-9200 ph1 by years end.
Sounds like a lot but its all smaller stuff - won't be earthshaking to sp unless something huge like amazing news in Waldenstrom's trial occurs.(I actually wouldn't be surprised to see this occur - given compatible gene specificity of drug/disease). After ravaging of biotech sector completes, the steady but unexciting forward progress of IDRA should give sp good support - but nothing earthshattering. I'll be accumulating this year - taking my time - long investment for me.
News 
Market Data 
Discover 
